Georgetown study finds GLP-1 weight loss draws more stigma than dieting

A new experimental study published April 9 in the American Psychological Association's journal Stigma & Health found that women who lost weight with GLP-1 medications were judged more harshly than women who lost the same amount of weight through diet and exercise — and that beliefs about a "shortcut" explained much of the gap ^[1][2].

The study, led by social psychologist Stacy Post, PhD, a postdoctoral researcher at Georgetown's Lombardi Comprehensive Cancer Center, recruited 402 US women ages 30 to 49 who identified as Black or white and who reported being overweight or having obesity ^[1][2]. Post conducted the research during her doctoral training at George Washington University ^[1].

What the study did

Participants were randomly assigned to read a short vignette about a woman named Evette who had lost 15% of her total body weight, either through diet and exercise or with a GLP-1 medication ^[1][2]. Evette was shown as either Black or white using a photo paired with the vignette; the images were pre-tested to rule out perceptual differences between the two women ^[1].

Participants then rated Evette on several stigma measures — fat phobia, dislike, blame, and desire for social distance — and reported whether they believed she had taken a weight-loss "shortcut" ^[1][2].

Stigma scores were higher when Evette lost weight with a GLP-1 than with diet and exercise ^[1][2]. Statistical analyses found that shortcut beliefs were the mechanism: perceiving GLP-1-assisted weight loss as an easy way out predicted higher fat phobia, greater dislike, more blame, and more desire for social distance ^[1][2].

A second finding surprised the researchers. Contrary to their hypothesis — which drew on intersectionality theory and predicted stronger stigma toward Black women — stigma was higher when Evette was portrayed as white rather than Black ^[2]. When Evette was described as white and as losing weight with a GLP-1, participants were more likely to endorse shortcut beliefs, which in turn predicted greater stigma ^[1][2]. The race of the participants themselves did not significantly change how the GLP-1 scenario and Evette's race together affected stigma through shortcut beliefs, which the authors say suggests these assumptions may operate similarly across groups ^[1][2].

The paper notes for context that clinical trials show GLP-1 and dual GIP/GLP-1 medications — semaglutide and tirzepatide are the examples given — can help people lose 15% to 20% of total body weight, along with benefits including cardioprotective effects, reduced blood pressure and lower cholesterol ^[2]. Georgetown's release states that more than 100 million people in America are clinically eligible to use GLP-1 medications such as Ozempic, Wegovy, Mounjaro or Zepbound for weight loss, and that roughly 18% of US adults are currently using or have previously used a GLP-1 drug ^[1].

Why it matters for patients

The findings put data behind something many people taking these drugs already describe. "GLP-1 medications can offer meaningful health benefits for people with obesity, but many patients report feeling shame and guilt for using them," Post said. "Our results show that the 'easy way out' perception does more than spark casual criticism. It can translate into measurable stigma, including fat phobia and a desire for social distance" ^[1].

Weight stigma is linked to harmful health outcomes, including stress, depressive and anxiety symptoms, body dissatisfaction, poor diet, and negative health behaviors ^[1][2]. The authors say stigma tied specifically to GLP-1 use may discourage some people from seeking evidence-based care, or may add shame for people already managing a chronic condition ^[1].

One practical takeaway: the judgment in this study did not come from strangers at large but from other women who themselves reported being overweight or having obesity ^[1][2]. That suggests people considering or using these medications may encounter the "shortcut" narrative even within communities that might seem sympathetic.

Important limits apply. This was a vignette experiment, not a study of real-world conversations or behavior, and the sample was limited to Black and white US women ages 30 to 49 ^[1][2]. Whether these reactions predict actual treatment decisions, prescription fills or adherence is not addressed in the sources.

The researchers call for communication strategies that better explain how GLP-1 medications work biologically, emphasize health outcomes, and reduce the perception that medication-assisted weight loss is inherently less legitimate than lifestyle approaches ^[1].

"Treatment decisions should be guided by health, not judgments about how someone manages their weight," Post said ^[1].

The authors report no personal financial interests related to the study ^[1]. Co-authors were Michelle L. Stock, PhD, of George Washington University and Susan Persky, PhD, of the National Human Genome Research Institute ^[1][2].